<DOC>
	<DOCNO>NCT02166047</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , efficacy GS-9620 virologically suppress adult chronic hepatitis B virus ( HBV ) infection currently treat oral antiviral ( OAV ) . Participants randomize 3 sequential cohort . Within cohort , participant randomize 1:3:3:3 ratio placebo one dose GS-9620 ( 1 , 2 , 4 mg ) participant continue current oral antiviral treatment entire duration study . Cohorts A , B , C consist different treatment period 4 , 8 , 12 week , respectively , follow Week 48 . After Cohort A complete treatment , safety review conduct external data monitoring committee prior begin Cohort B . Another safety review conduct Cohort B complete treatment prior begin Cohort C .</brief_summary>
	<brief_title>Safety Efficacy GS-9620 Treatment Chronic Hepatitis B Virus Virally-Suppressed Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<criteria>Must ability understand sign write informed consent form ; consent must obtain prior initiation study procedure Documented evidence chronic HBV infection ( e.g . HBsAg positive 6 month ) detectable HBsAg level screen Have approve HBV OAV treatment â‰¥ 1 year prior screening , HBV DNA low limit quantitation ( LLOQ ) , measure least , 6 month prior screen , HBV DNA &lt; 20 IU/ml screen Currently take approve HBV OAV ( tenofovir , entecavir , adefovir , lamivudine telbivudine , either single agent combination ) change regimen 3 month prior screen Willing provide blood sample tolllike receptor 7 ( TLR7 ) interleukin 28 B ( IL28B ) singlenucleotide polymorphism ( SNP ) assessment Must willing able comply study requirement Extensive bridge fibrosis cirrhosis Lab parameter within defined threshold neutropenia , anemia , thrombocytopenia , leukopenia , evidence inadequate liver function Coinfection hepatitis C virus ( HCV ) , HIV , hepatitis D virus ( HDV ) Evidence hepatocellular carcinoma Malignancy within 5 year prior screen , exception specific cancer cure surgical resection ( basal cell skin cancer , etc ) . Participants evaluation possible malignancy eligible Significant cardiovascular , pulmonary , neurological disease Any follow condition may worsen response interferon ( IFN ) : Autoimmune disease ( e.g . lupus erythematosus , rheumatoid arthritis , inflammatory bowel disease , sarcoidosis , moderate severe psoriasis ) Poorly control diabetes mellitus Significant psychiatric disorder Thyroid disorder ( unless control treatment ) Significant pulmonary disease ( e.g . chronic obstructive pulmonary disease ) Retinal disease Immunodeficiency disorder Received solid organ bone marrow transplant Received prolonged therapy immunomodulators ( e.g . corticosteroid ) biologics ( e.g . monoclonal Ab , interferon ) within 3 month screen Use another investigational agent within 3 month screen Current alcohol substance abuse judge investigator potentially interfere compliance Females pregnant may wish become pregnant study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Hepatitis B</keyword>
	<keyword>HBV</keyword>
	<keyword>GS-9620</keyword>
	<keyword>TLR-7 Agonist</keyword>
</DOC>